3 unknown, 2 active not recruiting. 4 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Unknown 3, Active not recruiting 1 |
| Phase 3 | 1 | Active not recruiting 1 |
Follow Li Zhang, MD: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Surufatinib Combined With Toripalimab and Chemotherapy in the Treatment of Non-Small Cell Lung Cancer Surufatinib, Toripalimab, Pemetrexed, Carboplatin/Cisplatin - Non Small Cell Lung Cancer | Phase 2 | Active not recruiting | Li Zhang, MD | 106 | 2022-01-06 | 2026-07-08 |
| Ensatinib Treat Second-generation ALK-TKI Resistance After Second-generation ALK-TKI Resistance Ensartinib - The Diagnosis Was ALK Positive NSCLC, Second Generation ALK-TKI is Resistant | Phase 2 | Unknown | Li Zhang, MD | 40 | 2021-12-01 | 2022-01-05 |
| An Open Label, Multicenter Phase 2 Study of Durvalumab (MEDI4736) + Olaparib as Maintenance Therapy in Chinese Durvalumab, etoposide, and cisplatin/carboplatin followed by durvalumab and olaparib - Lung Cancer, Small Cell Lung Cancer | Phase 2 | Unknown | Li Zhang, MD | 60 | 2021-08-21 | 2022-02-18 |
| Osimertinib Monotherapy or Combination With Chemotherapy for Advanced NSCLC Concurrent EGFR and TP53 Mutations Osimertinib, Pemetrexed, Carboplatin - Non-small Cell Carcinoma, EGFR Gene Mutation | Phase 3 | Active not recruiting | Li Zhang, MD | 294 | 2021-03-29 | 2025-10-15 |
| JS001 Combination Therapy in NSCLC Negative Driving Gene After First-line Chemotherapy. Toripalimab injection combine with Axitinib - Non-small Cell Lung Cancer | Phase 2 | Unknown | Li Zhang, MD | 50 | 2020-08-31 | 2020-07-07 |
Carcinoma, Non-Small-Cell Lung (2) · Lung Neoplasms (1) · Small Cell Lung Carcinoma (1)
Carboplatin (2) · Cisplatin (2) · Pemetrexed (2) · Axitinib (1) · Etoposide (1) · durvalumab (1) · ensartinib (1) · olaparib (1) · osimertinib (1) · surufatinib (1) · toripalimab (1)
China (5)